Nov 6, 2015

Anthera Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results

HAYWARD, Calif., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today provided a business update and reported financial results for the third quarter ended September 30, 2015.

Recent Developments and Business Highlights:

Clinical Development

Summary of Financial Results

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. Additional information on the Company can be found at

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about Anthera's expectations with respect to its public offering, including statements about its intended use of proceeds from the offering. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

(in thousands, except share and per share data)
 Three Months Ended 
September 30,
 Nine Months Ended 
September 30,
 2015 2014 2015 2014 
License revenue$ 548  $   $ 743  $   
Collaboration revenue  185        524      
Total revenues  733        1,267      
Operating Expenses:            
Research and development$ 10,359  $ 5,268  $ 24,893  $ 16,312  
General and administrative  2,091    1,419     5,694    4,849  
Research award  (367)       (1,467)     
Total operating expenses  12,083    6,687    29,120    21,161  
Loss from operations  (11,350)   (6,687)   (27,853)   (21,161) 
Other Expenses:            
Interest expense      (286)       (905) 
Other income (expense)  24    (14)   (28)   (93) 
Total other income (expense)  24    (300)   (28)    (998) 
Net loss$ (11,326) $ (6,987) $ (27,881) $ (22,159) 
Net loss per share attributable to common stockholders:            
Basic and diluted$ (0.29) $ (0.31) $ (0.81) $ (1.03) 
Weighted-average number of shares used in per share calculation: basic and diluted39,241,738 22,747,308 34,260,866 21,459,516 
(in thousands, except share data)
 September 30
 December 31
Cash and cash equivalents$ 55,762  $  2,639        
Accounts receivable$ 983  $         
Total assets$ 57,454   $  3,490        
Total deferred revenue$ 1,957  $  —        
Total liabilities, excludes deferred revenue$  10,187  $  5,751        
Accumulated deficit $ (344,692) $  (316,811)       
Total shareholders' equity (deficit)$ 45,310  $   (2,261)       
Common shares outstanding  39,875,405    23,005,209        


CONTACT: Nikhil Agarwal of Anthera Pharmaceuticals, Inc.

          or 510-856-5600x5621

Source: Anthera Pharmaceuticals, Inc.

News Provided by Acquire Media